29 June 2022, Wednesday ǀ 10:00 am to 12:00 pm (EDT)
Measures Taken for Improving Biosimilar Uptake and the
Potential Role of Healthcare Providers and Patients
Speakers' Presentations Available
Michael S Reilly, Esq Ralph McKibbin Professor Philip J Schneider
Executive Director MD, FACP, FACG, AGAF MS, FASHP, FASPEN, FFIP
Alliance for Safe Biologic President of the Pennsylvania Professor at The Ohio State Medicines Society of Gastroenterology University College of Pharmacy
Society of Gastroenterology
and the Digestive Disease
First ASBM/GaBI Biosimilar Webinar
Biosimilars have been in the market for 16 years since its first launch in 2006 in Europe, currently, there are 84 approvals in the EU and 35 in the US, representing almost 90% of the world market. While more biosimilars entering the healthcare system, there remains the need for broader information share and regular discussions to clarify and alleviate the concerns of biosimilars use for physicians and patients, specifically on the issues of prescribing practice and switching of biosimilars.
In this online event, we discussed key elements contributing to the wide uptake of biosimilars in Europe and the US and physicians’ trust in prescribing and switching of biosimilars. Presentations of concrete examples and experiences on challenges and uptake policies of biosimilars in Europe and the current status of market access of and successful uptake measures implemented for biosimilars in the US allow us to evaluate the role of healthcare providers (physicians, pharmacists) and health policymakers in biosimilars use.
An academic clinician with specialty in gastroenterology, a pharmacist, a patient advocate and a market access expert shared their experience with biosimilars, highlighting successes and challenges, their perspectives on prescribing and switching of biosimilars and measures to increase biosimilar adoption, including the role of healthcare providers.
Enhanced knowledge on biosimilars use will help provide
more affordable treatment choices for patients.
To gain an insight on key elements contributing to the wide uptake of biosimilars in Europe and the US
To hear the physicians’ trust in prescribing and switching of biosimilars
To understand the challenges and uptake policies of biosimilars in Europe
To examine the current status of market access of and successful uptake measures implemented for biosimilars in the US
To recognize patients’ concerns in biosimilars use
To evaluate the role of healthcare providers (physicians, pharmacists) and health policymakers in biosimilars use
To identify educational needs to enhance knowledge on biosimilars use
NEXT ONLINE EVENT!
ASBM–GaBI Biosimilar Webinar Series
This webinar is the first in a series.
The discussion will continue at the third webinar on ‘Ophthalmic Biosimilars’ in September 2022. More information will be available soon or contact us for more information!
Join the Club
Join our email list and get access to upcoming ASBM-GaBI webinars exclusive to our subscribers